Welcome to our dedicated page for Allakos news (Ticker: ALLK), a resource for investors and traders seeking the latest updates and insights on Allakos stock.
This page contains historical news coverage for Allakos Inc (ALLK), which operated as a biotechnology company focused on developing monoclonal antibody therapies. The company has been acquired and no longer operates independently. This archive provides context on the company's clinical development programs and the events surrounding its acquisition.
Allakos's news flow centered on clinical trial updates, particularly regarding lirentelimab, the company's investigational antibody targeting immune cell receptors. The news archive documents Phase 1 and Phase 2 trial results across multiple therapeutic areas, reflecting the company's strategy of evaluating its antibody platform in various immune-mediated conditions. For biotechnology companies, clinical trial announcements represent the most significant category of material news, as trial outcomes directly influence drug development prospects.
The historical news coverage also includes corporate developments such as business restructuring, board appointments, and financial reporting. These announcements provided insight into the company's strategic direction and operational status as it navigated the challenges of drug development. Biotechnology news typically follows this pattern of clinical updates interspersed with corporate and financial developments.
Browse this archive to understand Allakos's history as an independent biotech company, its clinical development trajectory, and the progression of events that led to its acquisition. This historical record offers perspective on the company's research activities and the typical development pathway for investigational therapeutics in the biotechnology sector.
Allakos Inc. (Nasdaq: ALLK) provided a business update on March 6, 2023, reporting financial results for Q4 and full year 2022. Key developments include the initiation of a Phase 2b study of lirentelimab for chronic spontaneous urticaria and continued enrollment for atopic dermatitis. The company reported Q4 2022 research and development expenses of $35.4 million, down from $72.9 million in Q4 2021, attributed to cost-cutting measures. General and administrative expenses also decreased to $10.8 million from $23.2 million. The net loss shrank to $43.0 million from $94.4 million year-over-year, and cash reserves stood at $279.8 million.
FAQ
What is the current stock price of Allakos (ALLK)?
What is the market cap of Allakos (ALLK)?
